These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 16259548)

  • 1. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.
    Papakostas GI; Petersen TJ; Kinrys G; Burns AM; Worthington JJ; Alpert JE; Fava M; Nierenberg AA
    J Clin Psychiatry; 2005 Oct; 66(10):1326-30. PubMed ID: 16259548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.
    Papakostas GI; Petersen TJ; Nierenberg AA; Murakami JL; Alpert JE; Rosenbaum JF; Fava M
    J Clin Psychiatry; 2004 Feb; 65(2):217-21. PubMed ID: 15003076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression.
    Rutherford B; Sneed J; Miyazaki M; Eisenstadt R; Devanand D; Sackeim H; Roose S
    Int J Geriatr Psychiatry; 2007 Oct; 22(10):986-91. PubMed ID: 17340654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
    Sheffrin M; Driscoll HC; Lenze EJ; Mulsant BH; Pollock BG; Miller MD; Butters MA; Dew MA; Reynolds CF
    J Clin Psychiatry; 2009 Feb; 70(2):208-13. PubMed ID: 19210951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study.
    Ozaki N; Otsubo T; Kato M; Higuchi T; Ono H; Kamijima K;
    Psychiatry Clin Neurosci; 2015 Jan; 69(1):34-42. PubMed ID: 24965202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
    Simon JS; Nemeroff CB
    J Clin Psychiatry; 2005 Oct; 66(10):1216-20. PubMed ID: 16259533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.
    Iosifescu DV; Nierenberg AA; Mischoulon D; Perlis RH; Papakostas GI; Ryan JL; Alpert JE; Fava M
    J Clin Psychiatry; 2005 Aug; 66(8):1038-42. PubMed ID: 16086620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open study of aripiprazole and escitalopram for psychotic major depressive disorder.
    Matthews JD; Siefert C; Dording C; Denninger JW; Park L; van Nieuwenhuizen AO; Sklarsky K; Hilliker S; Homberger C; Rooney K; Fava M
    J Clin Psychopharmacol; 2009 Feb; 29(1):73-6. PubMed ID: 19142112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
    Cheon EJ; Lee KH; Park YW; Lee JH; Koo BH; Lee SJ; Sung HM
    J Clin Psychopharmacol; 2017 Apr; 37(2):193-199. PubMed ID: 28129308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
    Fava M; Mischoulon D; Iosifescu D; Witte J; Pencina M; Flynn M; Harper L; Levy M; Rickels K; Pollack M
    Psychother Psychosom; 2012; 81(2):87-97. PubMed ID: 22286203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.
    Dording C; Cassiello C; King F; Pencina M; Fava M; Mischoulon D
    Int Clin Psychopharmacol; 2013 Sep; 28(5):238-44. PubMed ID: 23764521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.
    Masi G; Pfanner C; Millepiedi S; Berloffa S
    J Clin Psychopharmacol; 2010 Dec; 30(6):688-93. PubMed ID: 21105283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder.
    Matsunaga H; Hayashida K; Maebayashi K; Mito H; Kiriike N
    Int J Psychiatry Clin Pract; 2011 Nov; 15(4):263-9. PubMed ID: 22121999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: an open preliminary study.
    Fabrazzo M; Perris F; Monteleone P; Esposito G; Catapano F; Maj M
    Eur Neuropsychopharmacol; 2012 Feb; 22(2):132-6. PubMed ID: 21784621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies.
    Nelson JC; Mankoski R; Baker RA; Carlson BX; Eudicone JM; Pikalov A; Tran QV; Berman RM
    J Affect Disord; 2010 Jan; 120(1-3):133-40. PubMed ID: 19656577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
    Dunn RT; Stan VA; Chriki LS; Filkowski MM; Ghaemi SN
    J Affect Disord; 2008 Sep; 110(1-2):70-4. PubMed ID: 18272230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.